LYS228X
Total Payments
$49,849
Transactions
4
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2018 | $12,706 | 3 | 0 |
| 2017 | $37,143 | 1 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $49,849 | 4 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A FIRST IN HUMAN RANDOMIZED SUBJECT BLINDED PLACEBO CONTROLLED SINGLE AND MULTIPLE ASCENDING INTRAVENOUS DOSE STUDY TO ASSESS THE SAFETY TOLERABILITY AND PHARMACOKINETICS OF LYS228 IN HEALTHY SUBJECTS | Novartis Pharmaceuticals Corporation | $49,683 | 0 |
| A RANDOMIZED CONTROLLED EVALUATOR BLINDED MULTI CENTER STUDY TO EVALUATE LYS228 PHARMACOKINETICS CLINICAL RESPONSE SAFETY AND TOLERABILITY IN PATIENTS WITH COMPLICATED INTRA ABDOMINAL INFECTION | Novartis Pharmaceuticals Corporation | $82.77 | 0 |
| A RANDOMIZED CONTROLLED EVALUATOR BLINDED MULTI CENTER STUDY TO EVALUATE LYS228 PHARMACOKINETICS CLINICAL RESPONSE SAFETY AND TOLERABILITY IN PATIENTS WITH COMPLICATED URINARY TRACT INFECTION | Novartis Pharmaceuticals Corporation | $82.77 | 0 |
Top Doctors Receiving Payments for LYS228X
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Overland Park, KS | $49,849 | 4 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $49,849
- Total Doctors 0
- Transactions 4
About LYS228X
LYS228X is a drug associated with $49,849 in payments to 0 healthcare providers, recorded across 4 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharmaceuticals Corporation.
Payment data is available from 2017 to 2018. In 2018, $12,706 was paid across 3 transactions to 0 doctors.
The most common payment nature for LYS228X is "Unspecified" ($49,849, 100.0% of total).
LYS228X is associated with 3 research studies, including "A FIRST IN HUMAN RANDOMIZED SUBJECT BLINDED PLACEBO CONTROLLED SINGLE AND MULTIPLE ASCENDING INTRAVENOUS DOSE STUDY TO ASSESS THE SAFETY TOLERABILITY AND PHARMACOKINETICS OF LYS228 IN HEALTHY SUBJECTS" ($49,683).